SEARCH

SEARCH BY CITATION

References

  • Bal-Price A. and Brown G. C. (2001) Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 21, 64806491.
  • Bard F., Cannon C., Barbour R. et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916919.
  • Bard F., Barbour R., Cannon C. et al. (2003) Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl Acad. Sci. USA 100, 20232028.
  • Brown G. C. and Neher J. J. (2010) Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 41, 242247.
  • Bruhns P. (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 56405649.
  • Carty N. C., Wilcock D. M., Rosenthal A., Grimm J., Pons J., Ronan V., Gottschall P. E., Gordon M. N. and Morgan D. (2006) Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J. Neuroinflammation 10, 11.
  • Cizas P., Budvytyte R., Morkuniene R., Moldovan R., Broccio M., Losche M., Niaura G., Valincius G. and Borutaite V. (2010) Size-dependent neurotoxicity of beta-amyloid oligomers. Arch. Biochem. Biophys. 496, 8492.
  • Cooperstock M. S. (1974) Inactivation of endotoxin by polymyxin B. Antimicrob. Agents Chemother. 6, 422425.
  • Dalgediene I., Lasickiene R., Budvytyte R., Valincius G., Morkuniene R., Borutaite V. and Zvirbliene A. (2013) Immunogenic properties of amyloid beta oligomers. J. Biomed. Sci. 20, 10.
  • DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M. and Holtzman D. M. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 88508855.
  • Deshpande A., Mina E., Glabe C. and Busciglio J. (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 26, 60116018.
  • Fan R., Xu F., Previti M. L., Davis J., Grande A. M., Robinson J. K. and Van Nostrand W. E. (2007) Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J. Neurosci. 27, 30573063.
  • Ferrer I., Boada R. M., Sanchez Guerra M. and L., Rey M. J. and Costa-Jussa F. (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14, 1120.
  • Fossati-Jimack L., Ioan-Facsinay A., Reininger L. et al. (2000) Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J. Exp. Med. 191, 12931302.
  • Furlan R., Brambilla E., Sanvito F., Roccatagliata L., Olivieri S., Bergami A., Pluchino S., Uccelli A., Comi G. and Martino G. (2003) Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 126, 285291.
  • Gedvilaite A., Frommel C., Sasnauskas K., Micheel B., Ozel M., Behrsing O., Staniulis J., Jandrig B., Scherneck S. and Ulrich R. (2000) Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 273, 2135.
  • Hayashi M., Arai N., Satoh J., Suzuki H., Katayama K., Tamagawa K. and Morimatsu Y. (2002) Neurodegenerative mechanisms in subacute sclerosing panencephalitis. J. Child Neurol. 17, 725730.
  • Hillen H., Barghorn S., Striebinger A., Labkovsky B., Muller R., Nimmrich V., Nolte M. W., Perez-Cruz C. and van d. A., I, van L. F., van G. M., Bespalov A. Y., Schoemaker H., Sullivan J. P. and Ebert U. (2010) Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J. Neurosci. 30, 1036910379.
  • Hock C., Konietzko U., Streffer J. R. et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547554.
  • Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., Sandbrink R., Masters C. L. and Beyreuther K. (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271, 2290822914.
  • Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W. and Glabe C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486489.
  • Koenigsknecht-Talboo J. and Landreth G. E. (2005) Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25, 82408249.
  • Lambert M. P., Barlow A. K., Chromy B. A. et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 64486453.
  • Magga J., Puli L., Pihlaja R. et al. (2010) Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J. Neuroinflammation 7, 90.
  • Mclean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I. and Masters C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860866.
  • Minami S. S., Sidahmed E., Aid S. et al. (2010) Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Abeta/amyloid burden in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation 7, 57.
  • Mohajeri M. H., Gaugler M. N., Martinez J., Tracy J., Li H., Crameri A., Kuehnle K., Wollmer M. A. and Nitsch R. M. (2006) Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo. Neurodegener. Dis. 1, 160167.
  • Morgan D., Diamond D. M., Gottschall P. E. et al. (2001) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982985.
  • Nath A., Hall E., Tuzova M. et al. (2003) Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med. 3, 2939.
  • Neniskyte U., Neher J. J. and Brown G. C. (2011) Neuronal death induced by nanomolar amyloid beta is mediated by primary phagocytosis of neurons by microglia. J. Biol. Chem. 286, 3990439913.
  • Nicoll J. A., Wilkinson D., Holmes C., Steart P., Markham H. and Weller R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448452.
  • Nimmerjahn F. and Ravetch J. V. (2006) Fcgamma receptors: old friends and new family members. Immunity 2, 1928.
  • Nimmerjahn F., Bruhns P., Horiuchi K. and Ravetch J. V. (2005) FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 4151.
  • Orgogozo J. M., Gilman S., Dartigues J. F. et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 4654.
  • Petraityte-Burneikiene R., Nalivaiko K., Lasickiene R., Firantiene R., Emuzyte R., Sasnauskas K. and Zvirbliene A. (2011) Generation of recombinant metapneumovirus nucleocapsid protein as nucleocapsid-like particles and development of virus-specific monoclonal antibodies. Virus Res. 161, 131139.
  • Racke M. M., Boone L. I., Hepburn D. L. et al. (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25, 629636.
  • Ravetch J. V. and Kinet J. P. (1991) Fc receptors. Annu. Rev. Immunol. 9, 457492.
  • Rietschel E. T., Kirikae T., Schade F. U., Mamat U., Schmidt G., Loppnow H., Ulmer A. J., Zahringer U., Seydel U. and Di P. F. (1994) Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 8, 217225.
  • Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173177.
  • Schroeter S., Khan K., Barbour R. et al. (2008) Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 28, 67876793.
  • Sears D. W., Osman N., Tate B., McKenzie I. F. and Hogarth P. M. (1990) Molecular cloning and expression of the mouse high affinity Fc receptor for IgG. J. Immunol. 144, 371378.
  • Snyder S. W., Ladror U. S., Wade W. S., Wang G. T., Barrett L. W., Matayoshi E. D., Huffaker H. J., Krafft G. A. and Holzman T. F. (1994) Amyloid-β aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67, 12161228.
  • Solomon B., Koppel R., Hanan E. and Katzav T. (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl Acad. Sci. USA 93, 452455.
  • Song E. S., Young K. and Sears D. W. (1990) Rat and human natural killers exhibit contrasting immunoglobulin G subclass specificities in antibody-dependent cellular cytotoxicity reflecting differences in their Fc receptors (Fc gamma R). J. Leukoc. Biol. 48, 524530.
  • Takai T., Li M., Sylvestre D., Clynes R. and Ravetch J. V. (1994) FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 3, 519529.
  • Takata K., Hirata-Fukae C., Becker A. G. et al. (2007) Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur. J. Neurosci. 26, 24582468.
  • Tamura Y., Hamajima K., Matsui K., Yanoma S., Narita M., Tajima N., Xin K. Q., Klinman D. and Okuda K. (2005) The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol. Dis. 20, 541549.
  • Teeling J. L., Carare R. O., Glennie M. J. and Perry V. H. (2012) Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction. Acta Neuropathol. 124, 479490.
  • Weinshank R. L., Luster A. D. and Ravetch J. V. (1988) Function and regulation of a murine macrophage-specific IgG Fc receptor, Fc gamma R-alpha. J. Exp. Med. 167, 19091925.
  • Wilcock D. M., Rojiani A., Rosenthal A. et al. (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24, 61446151.
  • Zvirbliene A., Samonskyte L., Gedvilaite A., Voronkova T., Ulrich R. and Sasnauskas K. (2006) Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles. J. Immunol. Methods 311, 5770.
  • Zvirbliene A., Kucinskaite I., Sezaite I., Samuel D. and Sasnauskas K. (2007) Mapping of B cell epitopes in measles virus nucleocapsid protein. Arch. Virol. 152, 2539.